What Research Shows About Intermittent Fasting and Type 1 Diabetes

Intermittent fasting has become one of the most widely practiced eating patterns in the United States. Yet despite growing popularity and more than 225 published clinical trials—including nearly 40 focused on diabetes and prediabetes—major medical organizations have not added intermittent fasting to their official treatment guidelines.

A recent review published in The Lancet Diabetes & Endocrinology examines what the evidence actually shows across different types of diabetes. The findings suggest it may be time to reconsider how intermittent fasting is positioned in clinical care—though the picture differs significantly depending on diabetes type.

For adults with type 2 diabetes, the research is more extensive and encouraging. Multiple forms of intermittent fasting have been studied, including time-restricted eating (eating within a set window each day), the 5:2 diet (eating normally five days, eating very little two days), and fasting-mimicking diets.

These approaches tend to reduce HbA1c—a measure of average blood sugar over time—by roughly 0.3 to 1.2%. They also improve fasting glucose levels, 24-hour glucose patterns, and can support weight loss. Importantly, intermittent fasting appears to work about as well as traditional calorie restriction for managing blood sugar.

For people with type 1 diabetes, the evidence base is much smaller. Currently, there are not enough quality studies to recommend intermittent fasting as a standard approach. This doesn't mean it's unsafe or ineffective—it means researchers simply haven't gathered sufficient data in this population yet.

The gap in type 1 research is an important limitation to understand. Anyone with type 1 diabetes considering any significant dietary change should work closely with their healthcare team to monitor blood sugar patterns and insulin dosing adjustments.

One encouraging finding: when medications are adjusted using straightforward management rules, intermittent fasting does not appear to increase hypoglycemia (low blood sugar) risk in type 2 diabetes. This suggests the approach can be implemented safely with proper clinical oversight.

The review's authors argue that for type 2 diabetes, the evidence has matured enough to warrant inclusion in official clinical guidelines as one lifestyle option among several. For type 1 diabetes, more research is needed before such recommendations can be made.

Source: The lancet. Diabetes & endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.